<DOC>
	<DOC>NCT01023347</DOC>
	<brief_summary>This is a randomized clinical trial of Paclitaxel (Genexol®) and Cisplatin versus Paclitaxel loaded polymeric micelle (Genexol-PM®) and Cisplatin in advanced non small cell lung cancer.</brief_summary>
	<brief_title>A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological or cytological evidence of locally advanced, metastatic or recurrent NSCLC (stage IIIB or Iv) At least one measurable lesion(s) by RECIST criteria No previous palliative chemotherapy Age 18 or higher. ECOG PS 02 Life expectancy of at least 3 months. Adequate hematologic, hepatic, renal function Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul) Adequate liver function (≤ Total bilirubin ≤ 1.5 upper normal limit, ≤ AST/ALT x 2.5 upper normal limit, Alkaline phosphatase ≤ 2.5 upper normal limit) Adequate renal function (≤ serum creatinine 1.5 mg/dl) Written informed consent No prior chemotherapy for NSCLC Patients with malignancies (other than NSCLC), except for adequately treated nonmelanoma skin cancer or in situ carcinoma of the cervix. Peripheral neuropathy ≥ grade 2 (NCI CTC, version 3.0) Clinically significant cardiac disease (medically uncontrollable heart disease) Active infection or other serious medical illness Contraindication to any drug contained in the chemotherapy regimen Pregnant or lactating women were excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>NSCLC</keyword>
</DOC>